Real‐world outcomes in cardiac resynchronization therapy patients: design and baseline demographics of the SMART‐ Registry

Abstract

Aims The SMART (Strategic MAnagement to optimize response to cardiac Resynchronization Therapy) Registry was designed to assess real-world outcomes for patients receiving a cardiac resynchronization therapy defibrillator (CRT-D) and to better understand which programming and optimization techniques are used and how effective they are. Methods and results The SMART Registry is a global, multicentre, prospective, observational, post-market CRT-D registry with a planned enrolment of 2000 subjects from a maximum of 200 sites in Europe, North America, and Asia-Pacific region. Each subject will be followed up for a minimum of 12 months. The primary endpoint of CRT response rate at 12 months is defined by a clinical composite score of all-cause mortality, heart failure events, New York Heart Association Class, and quality of life as assessed by a patient global assessment instrument. A subgroup composed of the first 103 consecutive European subjects implanted with an NG4 device will have left ventricular multisite pacing feature enabled at any time during the initial 12 months of follow-up. The primary endpoint for this sub-analysis will be the NG4 PG-related complication-free rate at 36 months. Conclusions The SMART Registry achieved its recruitment target in August 2019, with 2014 patients enrolled. The baseline demographics demonstrated that patients were generally older, with greater co-morbidity, and on more contemporary medical therapy than in the key CRT trials. The results of the SMART Registry will determine which programming and optimization techniques are effective in this real-world population.

Vital real-world experience regarding Naoshuantong capsules for unselected ischemic stroke (VENUS): Rationale, design, and baseline of a prospective, multicenter, observational study

“…Similar to other large-scale, high-quality registry studies, formal hypotheses for sample size estimation are deficient in the VENUS registry ( Lei et al, 2020 ; Gardner et al, 2021 ). As a general rule, the sample size of the registry is supposed to be sufficient enough to represent the general population.…”

Functional impact of cardiac implanted devices on ipsilateral shoulder range of motion, scapular mobility, and self-reported quality of life

“…The number of cardiac implantable electronic device (CIED) implantations increases daily as the population ages, as they are used in the primary treatment and secondary prevention of heart diseases [ 1 – 3 ]. The positive effects of CIED implantation on the cardiovascular system are undeniable [ 4 – 6 ]. Still, although considered a minimally invasive procedure [ 7 ], recipients may be adversely affected due to early (acute) and late (chronic) procedural complications [ 8 ].…”

Efficacy and safety of different exercises in preventing cardiac implantable electronic device‐related shoulder impairment

“…Cardiac implantable electronic devices (CIEDs) significantly reduce morbidity and mortality by improving cardiac symptoms with appropriate indications 1–3 . Due to the increasing incidence of cardiovascular disease and the proven beneficial effects of CIEDs, the number of patients with such devices is constantly increasing 4…”